Progress towards the development of Klebsiella vaccines
Introduction: Klebsiella pneumoniae (KP) are a leading cause of healthcare-associated infections. The dramatic increase in microbial resistance to third-generation cephalosporin and carbapenem ‘front line’ antimicrobial agents and the paucity of new antimicrobials have left clinicians with few thera...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-07-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2019.1635460 |
| _version_ | 1797680365930807296 |
|---|---|
| author | Myeongjin Choi Sharon M Tennant Raphael Simon Alan S Cross |
| author_facet | Myeongjin Choi Sharon M Tennant Raphael Simon Alan S Cross |
| author_sort | Myeongjin Choi |
| collection | DOAJ |
| description | Introduction: Klebsiella pneumoniae (KP) are a leading cause of healthcare-associated infections. The dramatic increase in microbial resistance to third-generation cephalosporin and carbapenem ‘front line’ antimicrobial agents and the paucity of new antimicrobials have left clinicians with few therapeutic options and resulted in increased morbidity and mortality. Vaccines may reduce the incidence of infections thereby reducing the necessity for antimicrobials and are not subject to antimicrobial resistance mechanisms. Areas covered: We review whole cell, subunit, capsular polysaccharide (CPS), O polysaccharide (OPS) and conjugate vaccines against KP infection, as well as alternative KP vaccine platforms. Expert opinion: Vaccine-induced antibodies to KP CPS have been protective in preclinical studies, but the number of CPS types (>77) makes vaccines against this virulence factor less feasible. Since four OPS serotypes account of ~80% of invasive KP infections and anti-OPS antibodies are also protective in preclinical studies, both OPS-based conjugate and multiple antigen presenting system (MAPS) vaccines are in active development. Vaccines based on other KP virulence factors, such as outer membrane proteins, type 3 fimbriae (MrkA) and siderophores are at earlier stages of development. Novel strategies for the clinical testing of KP vaccines need to be developed. |
| first_indexed | 2024-03-11T23:28:57Z |
| format | Article |
| id | doaj.art-77c00aa0a9cf45e3a3c6c9c62fec279b |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:28:57Z |
| publishDate | 2019-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-77c00aa0a9cf45e3a3c6c9c62fec279b2023-09-20T10:18:04ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952019-07-0118768169110.1080/14760584.2019.16354601635460Progress towards the development of Klebsiella vaccinesMyeongjin Choi0Sharon M Tennant1Raphael Simon2Alan S Cross3University of Maryland School of MedicineUniversity of Maryland School of MedicineUniversity of Maryland School of MedicineUniversity of Maryland School of MedicineIntroduction: Klebsiella pneumoniae (KP) are a leading cause of healthcare-associated infections. The dramatic increase in microbial resistance to third-generation cephalosporin and carbapenem ‘front line’ antimicrobial agents and the paucity of new antimicrobials have left clinicians with few therapeutic options and resulted in increased morbidity and mortality. Vaccines may reduce the incidence of infections thereby reducing the necessity for antimicrobials and are not subject to antimicrobial resistance mechanisms. Areas covered: We review whole cell, subunit, capsular polysaccharide (CPS), O polysaccharide (OPS) and conjugate vaccines against KP infection, as well as alternative KP vaccine platforms. Expert opinion: Vaccine-induced antibodies to KP CPS have been protective in preclinical studies, but the number of CPS types (>77) makes vaccines against this virulence factor less feasible. Since four OPS serotypes account of ~80% of invasive KP infections and anti-OPS antibodies are also protective in preclinical studies, both OPS-based conjugate and multiple antigen presenting system (MAPS) vaccines are in active development. Vaccines based on other KP virulence factors, such as outer membrane proteins, type 3 fimbriae (MrkA) and siderophores are at earlier stages of development. Novel strategies for the clinical testing of KP vaccines need to be developed.http://dx.doi.org/10.1080/14760584.2019.1635460klebsiella pneumoniaeantimicrobial resistancevaccineconjugate vaccineo polysaccharidecapsular polysaccharidemaps vaccine |
| spellingShingle | Myeongjin Choi Sharon M Tennant Raphael Simon Alan S Cross Progress towards the development of Klebsiella vaccines Expert Review of Vaccines klebsiella pneumoniae antimicrobial resistance vaccine conjugate vaccine o polysaccharide capsular polysaccharide maps vaccine |
| title | Progress towards the development of Klebsiella vaccines |
| title_full | Progress towards the development of Klebsiella vaccines |
| title_fullStr | Progress towards the development of Klebsiella vaccines |
| title_full_unstemmed | Progress towards the development of Klebsiella vaccines |
| title_short | Progress towards the development of Klebsiella vaccines |
| title_sort | progress towards the development of klebsiella vaccines |
| topic | klebsiella pneumoniae antimicrobial resistance vaccine conjugate vaccine o polysaccharide capsular polysaccharide maps vaccine |
| url | http://dx.doi.org/10.1080/14760584.2019.1635460 |
| work_keys_str_mv | AT myeongjinchoi progresstowardsthedevelopmentofklebsiellavaccines AT sharonmtennant progresstowardsthedevelopmentofklebsiellavaccines AT raphaelsimon progresstowardsthedevelopmentofklebsiellavaccines AT alanscross progresstowardsthedevelopmentofklebsiellavaccines |